Research Article
Distinguishing Cardiac Amyloidosis and Hypertrophic Cardiomyopathy by Thickness and Myocardial Deformation of the Right Ventricle
Table 1
Baseline characteristics of patients of HCM and CA patients.
| | Parameters | Control subjects (n = 30) | HCM (n = 60) | CA (n = 60) | value (CA vs HCM) |
| | Age | 54 ± 12 | 55 ± 14 | 58 ± 10 | 0.676 | | Male (%) | 17 (57%) | 27 (45%) | 33 (55%) | 0.795 | | Body mass index, kg/m2 | 21.81 ± 1.85 | 23 ± 2.87 | 22 ± 3.09 | 0.318 | | Myocardial infraction | 0 (0%) | 0 (0%) | 0 (0%) | — | | Hypertension | 0 (0%) | 2 (3%) | 3 (5%) | — | | Diabetes | 0 (0%) | 2 (3%) | 2 (3%) | — | | Systolic pressure, mmHg | 121.7 ± 83.6 | 122 ± 15 | 113 ± 18 | 0.036 | | Diastolic pressure, mmHg | 78.9 ± 12.9 | 72 ± 10 | 73 ± 13 | 0.675 | | Myoglobin | — | 31.93 (25.04–45.55) | 50.96 (34.46–80.04) | 0.005 | | Creatine kinase isoenzyme | — | 3.27 (2.56–6.01) | 4.35 (2.33–6.46) | 0.086 | | NT-proBNP, pg/ml | 203 ± 105.4 | 1513 (656–3516) | 5803.5 (2533–13969) | 0.001 | | Troponin T | 0.7 ± 0.32 | 17.3 (11.9–45.3) | 91.9 (53.85–223.45) | 0.001 | | TG | — | 1.22 (0.89–2.06) | 1.29 (0.89–1.75) | 0.856 | | CHOL | — | 4.27 ± 1.61 | 4.09 ± 1.08 | 0.546 |
|
|
CA, cardiac amyloidosis; HCM, hypertrophic cardiomyopathy; NT-proBNP, N-terminal pro-brain natriuretic peptide; TG, triglyceride; CHOL, cholesterol. , , and versus controls. |
